Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings ...

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...